Molecular Characterization for Understanding Biliary Atresia

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorInstitut National de la Santé Et de la Recherche Médicale, France

About this trial

Although considered a rare disease, Biliary Atresia (BA) is the leading cause of neonatal cholestasis and liver transplantation in children. Little is known about the molecular mechanisms that drive BA. The purpose of this study is to collect the fluid samples, explanted liver tissue samples and dermal biopsy samples to enable investigators to perform the genetic and molecular analyses that might point to the gene(s) and cellular pathway involved in etiology of BA disease.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

confirmed diagnosis of biliary atresia in patients

parents of BA patients

Disqualifiers

no

Trial design

Design model

Single group

Treatments tested in this trial

  • blood sampling

    Other intervention

    collection of blood sample for preparation of DNA

  • skin biopsy sampling

    Other intervention

    preparation of primary cultures of dermal fibroblasts from skin biopsy sample

  • explanted liver of BA patients sampling

    Other intervention

    cryoconservation of liver tissue for molecular analyses

Treatment groups

100 Participants
are divided into 1 treatment group
Group A: BA patients and their parentsExperimental treatment 3 interventions

Trial outcomes

Primary outcomes

1

To identify the molecular mechanisms implicated in the etiology of BA

To identify gene(s) and cellular pathways affected in cells and liver tissue of BA patients: sequencing experiments

Time frame
10 Years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.